PF-07284892

COMBINATION_PRODUCT2 trials

Sponsors

Pfizer

Conditions

Carcinoma, Non-Small-Cell LungCarcinoma, Pancreatic DuctalColorectal NeoplasmsSolid Tumor

Phase 1

PF-07284892 in Participants With Advanced Solid Tumors

TerminatedNCT04800822

PfizerSolid Tumor

Start: 2021-03-17End: 2024-06-19Updated: 2024-10-22

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Active, not recruitingNCT06704724

PfizerCarcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Colorectal Neoplasms

Start: 2024-12-10End: 2029-03-11Updated: 2026-03-13

Related Papers

A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.

Journal of Clinical Oncology2023-06-016 citations